Piramal Pharma Q2 Results Review: Motilal Oswal Maintains ‘Buy’ Rating Despite Near-Term Challenges
Piramal Pharma Q2 Results Review: Key Takeaways for Investors Motilal Oswal has maintained its ‘Buy’ rating on Piramal Pharma Ltd. despite the company facing near-term headwinds. In this article, we will delve into the key takeaways from the Q2 results and analyze the factors that are expected to impact the company’s performance in the coming […]